Skip to content

Benefit of Tin Filter in Regards to Image Quality and Radiation Dose in CT Scan Study of Pulmonary Parenchyma

Benefit of Tin Filter in Regards to Image Quality and Radiation Dose in CT Scan

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04119141
Enrollment
25
Registered
2019-10-08
Start date
2019-05-10
Completion date
2020-06-30
Last updated
2019-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Parenchyma, Tin X Ray

Brief summary

Main objective: to demonstrate that the diagnostic quality associated with the acquisition mode with tin filter, evaluated in a subjective way, is not inferior to that associated with the acquisition mode without filter.

Detailed description

The chest x-ray is the first-line exam for the study of pulmonary parenchyma. Nevertheless, it does not make it possible to reveal all pulmonary pathologies, and in particular those of very small sizes. Thanks to its very high spatial resolution and contrast resolution, the scanner is able to detect all infra-millimetric pathologies of the pulmonary parenchyma but also mediastinal pathologies that could not have been seen on the standard x-ray. This study fits into the context of pleural pathology screening for patients exposed to asbestos in their professional environment. Today, the chest CT scan in millimetric sections isth e standardised method used in the context of this screening.Tin filtration is an additional filtration at the output of the X-ray tube made available on premium Siemens scanners. In diagnostic medical imaging, the photon beam has an energetic spectrum ranging from 0 to 150 keV. However the weak energies do not participate in the formation of the image but, on the other hand, to the overall radiation of the patient. The purpose of the addition of the tin filter is to be able to suppress, at the output of the tube, all low and medium energy levels, only allowing high energy levels to pass through. A previous study comparing the same group of patients on two different machines (one with tin filtration, one without tin filtration) showed a significant decrease in the radiation dose; nevertheless, a certain number of parameters differed between the two scanners used. In order to get rid of the different biases encountered on previous published studies, we propose to carry out this study on the same machine, by activating and deactivating tin filtration, all other parameters of acquisition and reconstruction of the image being equal in all respects.

Interventions

DIAGNOSTIC_TESTX ray imaging

Acquisition: * 140 kVp, * 1/2 mAs/kg, * Pitch: 1.35, * Rotation time: 0.5 sec. Reconstruction: * I70f filter, 3 iteration loops, * Cutting thickness 1 mm/0.7 mm * Fenestration: C -600/W 1600 * Field of view (Size, x & y coordinates) identical on both acquisitions.

Sponsors

Dr Béatrice Daoud
CollaboratorUNKNOWN
Ramsay Générale de Santé
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
DEVICE_FEASIBILITY
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient aged 18 and over. * Patient referred for chest CT scan in the context of screening or monitoring of occupational exposure to asbestos. * Patient with health insurance or beneficiary of a social security scheme. * Patient having given their express consent.

Exclusion criteria

* Woman who is pregnant or likely to be pregnant. * Lactating or parturient women * Minors. * Protected patients: Adults under trusteeship, guardianship or other legal protection, deprived of liberty by judicial or administrative decision; hospitalised without consent.

Design outcomes

Primary

MeasureTime frameDescription
Likert score scale score1 hourPrimary endpoint: score obtained on the Likert scale.

Countries

France

Contacts

Primary ContactJean Francois OUDET
jeanfrancois.oudet@free.fr+33683346567
Backup ContactMarie Barba
mh.barba@ecten.eu+330664888704

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026